Send us Fan Mail This week on Just MS News, we reviewed 139 MS-related articles from June 22–28, 2026, and narrowed them down to the stories most worth your time. The lead story this week is early, but meaningful: PTD802, an oral remyelination therapy, has been cleared for its first human trial. It is not an approved treatment, and it is not a cure. But for people living with MS, research focused on myelin repair is worth paying attention to. We also cover Sanofi’s Cenrifki, also known as tolebrutinib, being approved in Europe for adults with non-relapsing secondary progressive MS. This is one of the biggest confirmed treatment stories of the week, especially for progressive MS, but it also comes with important safety monitoring. Other stories this week include blood-based NfL testing for MS monitoring, early high-efficacy treatment in childhood-onset MS, light therapy glasses for MS-related fatigue, menopause and cognition, balance training, cognitive coaching, ocrelizumab and rituximab infection-risk research, vision recovery research, and a human story from the National MS Society called “From Patient to Researcher: How MS Changed My Path.” As always, this is not medical advice. Just MS News is a calm weekly recap meant to help people living with MS, caregivers, advocates, and supporters understand what is happening in MS news without the overload. Main Story LinksPTD802 oral remyelination therapy https://www.neurologylive.com/view/fda-clears-investigational-new-drug-application-remyelinating-agent-ptd802-multiple-sclerosisCenrifki approved in Europe for non-relapsing SPMS https://pmlive.com/sanofis-cenrifki-approved-in-europe-for-secondary-progressive-ms-without-relapses/Blood-based NfL testing and MS monitoring https://www.technologynetworks.com/tn/blog/how-blood-based-nfl-testing-could-transform-multiple-sclerosis-management-414010Early high-efficacy treatment in children with MS https://www.msaustralia.org.au/news/early-treatment-with-highly-effective-therapy-could-reduce-long-term-disability-in-children-with-ms/Light therapy glasses for MS fatigue https://www.nature.com/articles/s41598-026-56950-3Menopause and MS cognition https://www.neurologyadvisor.com/features/menopause-and-multiple-sclerosis-neurologic-manifestations/Balance training for MS https://clinician.nejm.org/balance-training-multiple-sclerosis-nejm-jw.NA46017Mindset coaching for MS cognitive symptoms https://multiplesclerosisnewstoday.com/news-posts/2026/06/22/trial-target-ms-cognitive-symptoms-mindset-coaching/Ocrelizumab and rituximab serious infection risk https://verahealth.ai/fr/news/multiple-sclerosis-ocrelizumab-and-rituximab-show-similar-serious-infection-riskVision recovery research https://iovs.arvojournals.org/article.aspx?articleid=2814516From Patient to Researcher: How MS Changed My Path https://www.nationalmssociety.org/news-and-magazine/momentum-magazine/from-the-community/from-patient-to-researcher-ms-changed-my-path The Just MS (Multiple Sclerosis) Show, w host Justin Loizos, is a podcast that connects, educates and tries to uplift others living with multiple sclerosis. It provides real-life stories, interviews, and information about DMTs (disease modification therapies) and updates on research developments. www.justmultiplesclerosis.com